Introduction
============

Thyroid cancer (TC) is a frequently occurring malignant tumor with steadily increasing incidence ([@b1-mmr-22-03-2199]--[@b5-mmr-22-03-2199]). In 2018, the American Cancer Society predicted that there would be 53,990 newly diagnosed patients with TC that year ([@b6-mmr-22-03-2199]). Based on histopathological examination, TC is divided into 4 subtypes: Anaplastic thyroid carcinoma, papillary thyroid carcinoma, medullary thyroid cancer and follicular thyroid cancer ([@b7-mmr-22-03-2199]--[@b9-mmr-22-03-2199]). Different hypotypes of TC lead to various clinical outcomes. A number of studies have reported that intricate biological processes participating in the interactions between polygenes may contribute to the occurrence and progression of TC ([@b10-mmr-22-03-2199]--[@b12-mmr-22-03-2199]). Previous studies have suggested that hsa-miR-200a-5p and hsa-miR-181a-2-3p could be applied for latent diagnostic and prognostic biomarkers of TC ([@b13-mmr-22-03-2199],[@b14-mmr-22-03-2199]). Nevertheless, the clinical characteristics of molecular profiles in TC have yet to be elucidated. Therefore, to further understand the molecular mechanisms of TC, an multi-method study may offer novel insight for TC prevention and treatment ([@b15-mmr-22-03-2199]).

MicroRNAs (miRNAs/miRs) contain \~19--25 nucleotides and are endogenous non-coding RNAs with gene-regulating functions ([@b16-mmr-22-03-2199]--[@b19-mmr-22-03-2199]). miRNAs are critical in the biological processes of diversified human carcinomas. For instance, they participate in extensive biological actions, including cell proliferation, invasion and apoptosis ([@b18-mmr-22-03-2199],[@b20-mmr-22-03-2199]--[@b23-mmr-22-03-2199]). Previous studies have demonstrated that miR-193a-3p is a neoplasm suppressor in various carcinomas, including hepatocellular cancer ([@b24-mmr-22-03-2199]), gastric cancer ([@b25-mmr-22-03-2199],[@b26-mmr-22-03-2199]), lung carcinoma ([@b27-mmr-22-03-2199]), breast carcinoma ([@b28-mmr-22-03-2199]) and colorectal carcinoma ([@b29-mmr-22-03-2199],[@b30-mmr-22-03-2199]). To the best of the authors\' knowledge, thus far only one study has investigated the association between miR-193a-3p and medullary thyroid carcinoma ([@b31-mmr-22-03-2199]); however, a limitation of this study was the small sample size, which prevented a comprehensive description and analysis of TC. To further comprehend the potential molecular mechanisms, it is necessary to examine miR-193a-3p expression in TC using a larger volume of data.

Cyclin D1 (CCND1), a member of the highly conserved cyclin family, can function as a modulator of cyclin-dependent kinase (CDK)4 or CDK6, and has an important role in adjusting the progression of the cell cycle ([@b32-mmr-22-03-2199],[@b33-mmr-22-03-2199]). Previous studies revealed that CCND1 has a crucial role in promoting proliferation, migration and tumor metastasis ([@b34-mmr-22-03-2199],[@b35-mmr-22-03-2199]) in cancers such as lung cancer ([@b33-mmr-22-03-2199]), gastric cancer ([@b36-mmr-22-03-2199]) and renal cell cancer ([@b37-mmr-22-03-2199]). CCND1 has been reported to exhibit a high expression in TC tissues and to be associated with invasive behavior ([@b38-mmr-22-03-2199]).

The present study examined TC specimen information from The Cancer Genome Atlas (TCGA) to assess the expression levels of miR-193a-3p and CCND1, and their association with clinical parameters. The data of miR-193a-3p and CCND1 were extracted and validated via ArrayExpress databases and the Gene Expression Omnibus (GEO). Then, the candidate target genes of miR-193a-3p were identified using miRWalk 3.0 and overlapped with the upregulated genes in TC identified using TCGA database. The miR-193a-3p candidate target genes were further investigated using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein-protein interaction (PPI) network enrichment analyses. According to the bioinformatics analysis of the present study, a hub gene was found in TC, and the targeting regulatory relations between the hub gene and miR-193a-3p were confirmed by a dual luciferase assay. By performing a meta-analysis and bioinformatics analysis, the present study revealed the latent molecular mechanisms of miR-193a-3p, as well as its associations with the identified hub gene, which may lead to TC.

Materials and methods
=====================

### miR-193a-3p expression in TC from public databases and the literature

TCGA is a pool of molecular datasets for at least 30 types of cancers, including TC ([@b39-mmr-22-03-2199]). The present study explored TCGA to determine miR-193a-3p expression in TC tissues. miRNA expression data of 510 TC and 59 normal samples were acquired, along with the accompanying clinical information, from TCGA, up to December 1, 2018 ([@b40-mmr-22-03-2199]). Chip datasets (GSE40807, GSE62054 and GSE73182) from GEO were also searched to examine the profiling of miR-193a-3p expression in TC ([@b41-mmr-22-03-2199]--[@b43-mmr-22-03-2199]). The following keywords were used: (papillary OR medullary OR follicular OR anaplastic OR thyroid) AND (carcinoma OR cancer OR adenocarcinoma OR tumor OR neoplas\* OR malignan\*) AND (microRNA OR miR OR miRNA), where '\*' refers to a wildcard search. The public database of microarray gene expression, ArrayExpress (E-MTAB-736) ([@b44-mmr-22-03-2199]) was also used. In addition, literature that included miR-193a-3p expression in TC was searched for in 13 online databases: Wiley Online Library (<https://onlinelibrary.wiley.com>), Ovid (<https://www.ovid.com>), LILACS (<https://lilacs.bvsalud.org>), Web of Science (<http://www.isiknowledge.com>), PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), Science Direct (<https://www.sciencedirect.com>), Cochrane Central Register of Controlled Trials (<https://www.cochranelibrary.com>), EMBASE (<https://www.embase.com>), Google Scholar (<https://scholar.google.com>), Chong Qing VIP (<http://lib.cqvip.com>), Wan Fang (<http://www.wanfangdata.com>), Chinese CNKI (<https://www.cnki.net>) and the China Biology Medicine Disc (<http://www.sinomed.ac.cn>). The studies needed to meet the following requirements for inclusion: i) The miR-193a-3p expression data in TC could be tested in humans; and ii) the relevant information of miR-193a-3p could be abstracted from the literature. All expression data and clinical information connected to miR-193a-3p were extracted.

### Comprehensive statistical analysis of TCGA, GEO, ArrayExpress and the literature

The expression levels of both TC and non-cancerous samples were visualized using scatter diagrams and receiver operating characteristic (ROC) curves created using GraphPad Prism 6.0 (GraphPad Software, Inc.). Student\'s t-test was performed to compare the expression of TC and non-cancer samples, as well as the association between clinicopathological parameters and miR-193a-3p from TCGA database. One-way analysis of variance was used for three or more groups. All miR-193a-3p expression data abstracted from various databases were normalized to log2, and P\<0.05 was considered to indicate a statistically significant difference. An all-sided analysis was performed by employing STATA 12.0 software (StataCorp LLC). The pooled standard mean difference (SMD) was applied to evaluate miR-193a-3p expression. χ^2^ and I^2^ tests were computed to assess the heterogeneity within the meta-analysis. The Mantel-Haenszel fixed-effects model was selected if there was no prominent heterogeneity (I^2^\<50%). Otherwise, a random-effects model was applied (I^2^\>50%) ([@b45-mmr-22-03-2199]); meanwhile, heterogeneity analysis was performed to discover the sources of heterogeneity. Subsequently, a summary (s)ROC was created to indicate the ability of miR-193a-3p to identify TC compared with a normal sample ([@b46-mmr-22-03-2199]--[@b48-mmr-22-03-2199]).

### Prediction of miR-193a-3p candidate target genes and their molecular functions

To further search for the latent molecular functions of miR-193a-3p in TC, bioinformatics analysis was performed. First, the target genes of miR-193a-3p were predicted using 12 platforms \[miRWalk 2.0 (version 2; <http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2>), PITA (version 6; <http://genie.weizmann.ac.il/pubs/mir07/mir07_exe.html>), PicTar2 (<https://pictar.mdc-berlin.de>), RNAhybrid 2.1 (<https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid>), MicroT4 v4.0 (version 5; <http://diana.imis.athena-innovation.gr>), miRDB 4.0 (<http://www.mirdb.org>), miRanda-rel2010 (<http://www.microrna.org/microrna/getDownloads.do>), TargetScan 7.2 (version 7.2; <http://www.targetscan.org>), RNA22 v2 ([https://cm. jefferson.edu/rna22-full-sets-of-predictions](https://cm. jefferson.edu/rna22-full-sets-of-predictions)), miRBridge (<http://www.ncbi.nlm.nih.gov/pubmed/?term=20385095>), miRNAMap (ftp://mirnamap.mbc.nctu.edu.tw/miRNAMap2) and miRMap (<https://mirmap.ezlab.org>)\]. The predicted genes exhibited in the 12 platforms were selected: 3,984 candidate target genes. Log2 conversion and normalization was performed for the gene chips and RNA sequencing from the GEO and TCGA databases. Differentially expressed genes in microarrays and RNA sequencing data were also screened out by the limma package (version 3.42.2) of R language (R version 3.6.2; <http://www.r-project.org>) ([@b49-mmr-22-03-2199]). Integration of differentially expressed genes identified from gene chips and RNA sequencing was conducted via RobustRankAggreg (version 1.1; <https://cran.r-project.org/web/packages/RobustRankAggreg>). The overexpressed genes in TC from the TCGA and GEO databases were calculated by selecting the following criteria: P-adj\<0.05 and any upregulated genes with a log2-fold change (FC)\>1. The candidate target genes obtained with the online prediction tools in TCGA and GEO were then overlapped and presented as Venn diagrams ([@b50-mmr-22-03-2199]). Then, the overlapping target genes were used to study molecular mechanisms via GO ([@b51-mmr-22-03-2199]), KEGG pathway ([@b52-mmr-22-03-2199]), Disease Ontology (DO) ([@b53-mmr-22-03-2199]) and PPI network analyses. Bioinformatics analyses were implemented using clusterprofiler package (version 3.10) of R language ([@b54-mmr-22-03-2199]). The ggplot2 package (version 3.3.0) from R language was utilized to visualize the results of the functional analysis ([@b55-mmr-22-03-2199]). STRING 11.0 (<http://string.embl.de>) was also used to generate a PPI network, which revealed the connection among the overlapping related genes ([@b56-mmr-22-03-2199]).

### Expression of CCND1 in TC samples from the TCGA and GEO databases

The clinical value of CCND1, whose expression data was extracted from GEO and TCGA, was further explored. CCND1 expression data and its clinical information were acquired from TCGA. The GEO database was also mined to obtain chip datasets from TC samples using the following keywords: (papillary OR medullary OR follicular OR anaplastic OR thyroid) AND (carcinoma OR tumor OR cancer OR adenocarcinoma OR neoplas\* OR malignan\*) AND (Cyclin D1 OR G1/S-Specific Cyclin-D1 OR PRAD1 Protein OR B-Cell CLL/Lymphoma 1 OR U21B31 OR BCL-1 Oncogene OR BCL1 OR PRAD1 Oncogene OR Parathyroid Adenomatosis 1 OR D11S287E OR B-Cell Lymphoma 1 Protein). Filtering condition: Series \[Entry type\], Homo sapiens \[Organism\]. A total of 13 datasets were obtained: GSE3678, GSE6004, GSE6339, GSE9115, GSE27155, GSE29265, GSE33630, GSE35570, GSE50901, GSE53072, GSE53157, GSE58689 and GSE65144 ([@b57-mmr-22-03-2199]--[@b67-mmr-22-03-2199]). Statistical analysis of CCND1 was also performed. The methods used were the same as those used above for evaluating the expression of miR-193a-3p.

### Cell culture and transfection

The 293 cell line was obtained from Huzhou Hippo Biotechnology Co., Ltd. and cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin. Cells were cultured in an incubator at 37°C with 5% CO~2~. miR-193a-3p mimic (5′-AACUGGCCUACAAAGUCCCAGU-3′), miR-146b-5p mimic (5′-UGAGAACUGAAUUCCAUAGGCUG-3′) and mimic control (5′-UUUGUACUACACAAAAGUACUG-3′) were synthesized and obtained from Hippobio Co., Ltd. miR-193a-3p mimic, miR-146b-5p mimic and their mimic control (all 75 pM) were transfected into 2.5×10^5^ 293 cells/well using Lipofectamine^®^ 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. Transfection efficiency was measured by reverse transcription-quantitative PCR (RT-qPCR) after 48 h.

### RNA extraction and RT-qPCR

Cellular RNA was extracted from 293 cells with TRIzol^©^ reagent (Tiangen Biotech Co., Ltd.). RevertAid Reverse Transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) was used to reverse transcribe miRNA according to the manufacturer\'s protocol. The expression of miR-193a-3p and miR-146b-5p was performed by qPCR using PerfectStart Green qPCR SuperMix (Transgen Biotech Co., Ltd.) on an ABI Q1 RT-qPCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). U6 was used as an internal reference. The relevant primer sequences were as follows: miR-193a-3p forward, 5′-GCCGAGAACTGGCCTACAAA-3′ and reverse, 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACTGGGAC-3′; miR-146b-5p forward, 5′-GCCGAGTGAGAACTGAATTCC-3′ and reverse, 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCAGCCTAT-3′; U6 forward, 5′-CTCGCTTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCACGAATTTGCGT-3′. miR-193a-3p and miR-146b-5p expression levels were calculated by the 2^−∆∆Cq^ method ([@b68-mmr-22-03-2199]).

### Validation of the association between miR-193a-3p and the hub gene

The protein with the most connections was selected for further investigation. 293 cells exhibit a high transfection efficiency and were thus selected for the luciferase activity assay. The wild-type (Wt) CCND1-3′ untranslated region (UTR) and seed region mutant (Mut) of the miR-193a-3p binding site were subcloned into the pGL3 system (Promega Corporation). Its corresponding positive control \[Wt tumor necrosis factor receptor-associated factor 6 (TRAF6)-3′ UTR + miR-146b-5p\] was also subcloned into the pGL3 system ([@b69-mmr-22-03-2199],[@b70-mmr-22-03-2199]). Subsequently, 1×10^5^ 293 cells/well were co-transfected with 100 ng Wt CCND1-3′ UTR or Wt TRAF6-3′ UTR vector and 400 ng miRNA mimic or negative control (NC) plasmid using X-tremeGENE™ HP DNA transfection reagent \[Roche Diagnostics (Shanghai) Co., Ltd.\]. Then, 2 days following incubation, firefly luciferase activity was assessed using a Dual-Luciferase Reporter assay system (Promega Corporation) in accordance with the manufacturer\'s protocols. Firefly luciferase activity was normalized to *Renilla* luciferase activity. Student\'s t-test was used to compare mimics and mimic control for each luciferase plasmid. Pearson\'s correlation analysis was also conducted to analyze the relationship between miR-193a-3p and CCND1, and P\<0.05 was considered to indicate a statistically significant difference. Hub gene expression between the TC samples and the normal samples was explored via immunohistochemistry using The Human Protein Atlas ([@b71-mmr-22-03-2199]).

Results
=======

### Downregulated miR-193a-3p expression in TC and its clinical significance from TCGA

The expression of miR-193a-3p in the TC group was 3.00±0.75 and that in the non-cancerous group was 3.88±0.73. miR-193a-3p exhibited significantly reduced expression in 510 TC samples compared with in 59 non-cancer controls (P\<0.001; [Fig. 1A](#f1-mmr-22-03-2199){ref-type="fig"}). The ROC curve of miR-193a-3p was computed with an area under the curve (AUC) of 0.802 (P\<0.001; [Fig. 2A](#f2-mmr-22-03-2199){ref-type="fig"}), which reflected the moderate value of miR-193a-3p to differentiate TC from the non-cancerous groups. The cut-off value was 3.444 (sensitivity 71.2% and specificity 79.7%). miR-193a-3p expression and clinical parameters are displayed in [Table I](#tI-mmr-22-03-2199){ref-type="table"}. The miR-193a-3p levels in females were notably greater than those in males (P=0.004). miR-193a-3p was markedly decreased in individuals ≤60 years of age compared with those \>60 years (P=0.020). ln addition, the number of distant metastases showed a negative association with miR-193a-3p expression levels (P=0.048).

### miR-193a-3p expression in TC verified via GEO, ArrayExpress and literature analyses

Subsequently, in other online databases, data from 4 chips (GSE40807, GSE62054, GSE73182 and E-MTAB-736) were acquired from the GEO and ArrayExpress databases, which provided the expression information on miR-193a-3p in 88 TC and 75 non-cancerous tissues ([Table II](#tII-mmr-22-03-2199){ref-type="table"}). The literature was also searched in 13 online databases, but the data from one study could not be extracted. All 4 datasets obtained from the GEO and ArrayExpress databases revealed that miR-193a-3p expression levels in TC were greater compared with non-TC controls, although two of these four datasets had P-values \>0.05 ([Fig. 1B-E](#f1-mmr-22-03-2199){ref-type="fig"}). ROC analysis was also used to estimate the capacity of miR-193a-3p in distinguishing TC from non-cancer tissues ([Fig. 2B-E](#f2-mmr-22-03-2199){ref-type="fig"}); three of the four chips demonstrated that miR-193a-3p had a moderate diagnostic value for TC. miR-193a-3p expression data from TCGA, GEO and ArrayExpress, which provided 598 TC and 134 non-cancerous samples, were combined for meta-analysis. The SMD of miR-193a-3p was −1.00 \[P\<0.001; 95% CI, (−1.21, −0.79); [Fig. 3A](#f3-mmr-22-03-2199){ref-type="fig"}\] via the fixed-effects model, and the heterogeneity test was P=0.46 (I^2^=0%). The AUC of the sROC was 0.80 (95% CI, 0.76--0.83), indicating a moderate ability to differentiate TC from non-cancer samples. The combined sensitivity and specificity were 0.69 (95% CI, 0.59--0.78) and 0.82 (95% CI, 0.67--0.91), respectively ([Fig. 3B](#f3-mmr-22-03-2199){ref-type="fig"}). Publication bias was performed and showed that there was no conspicuous publication bias among the datasets (Begg\'s test and Egger\'s test were 0.81 and 0.16, respectively; [Fig. 3C and D](#f3-mmr-22-03-2199){ref-type="fig"}).

### GO annotation, KEGG pathway, DO and PPI network analysis

The prediction of the candidate target genes of miR-193a-3p was conducted using miRWalk 3.0, in which 3,984 potential mRNA candidate target genes were discovered. Next, 1,490 and 132 genes with elevated expression were determined from the TCGA and GEO databases, respectively. A total of 28 overlapping genes were eventually identified ([Fig. 4A](#f4-mmr-22-03-2199){ref-type="fig"}). The properties of these target genes were analyzed using the clusterprofiler R package. The results indicated that 'response to nutrient levels' was the most significantly enriched biological process (BP); with respect to cellular components (CC), the genes were mainly enriched in the 'lamellar body'. In terms of molecular function (MF), 'sulfur compound binding' was the most enriched ([Fig. 5A-C](#f5-mmr-22-03-2199){ref-type="fig"}; [Table III](#tIII-mmr-22-03-2199){ref-type="table"}). However, no KEGG pathways were significantly enriched with these genes. DO analysis was also performed to discover related diseases caused by these genes. The results identified that 'cell type benign neoplasm' was the most enriched ([Fig. 5D](#f5-mmr-22-03-2199){ref-type="fig"}; [Table III](#tIII-mmr-22-03-2199){ref-type="table"}). Then, the target genes were put into the STRING online website to construct a protein-protein interaction network ([Fig. 4B](#f4-mmr-22-03-2199){ref-type="fig"}). In the present study, CCND1 attracted attention as a hub gene, as it had the most connections among the proteins; therefore, the targeting association between CCND1 and miR-193a-3p was selected for further investigation.

### Overexpression of CCND1 in TC and its clinical significance

The expression value and clinical significance of CCND1 in TC was verified using data from two different sources (TCGA and GEO databases; [Table IV](#tIV-mmr-22-03-2199){ref-type="table"}). The expression of CCND1 in the TC group from TCGA database was 13.36±0.74 and that in the non-cancerous group was 11.66±0.49. CCND1 was significantly overexpressed in 513 TC samples compared with 59 non-cancerous samples (P\<0.001; [Fig. 6A](#f6-mmr-22-03-2199){ref-type="fig"}). The AUC for upregulated CCND1 expression in TC was 0.965 (P\<0.001; [Fig. 7A](#f7-mmr-22-03-2199){ref-type="fig"}), which indicated the high capacity of the expression value of CCND1 to differentiate TC from normal samples. The cut-off value was 12.628 (sensitivity 86.9% and specificity 100%). Differential CCND1 expression was not detected for the clinical pathological parameters analyzed. The associations between the expression of CCND1 and clinical pathological parameters are summarized in [Table V](#tV-mmr-22-03-2199){ref-type="table"}. The expression value of CCND1 was also calculated from the chip arrays of the GEO database, which included 384 TC and 316 non-cancer controls (GSE3678, GSE6004, GSE6339, GSE9115, GSE27115, GSE29265, GSE33630, GSE35570, GSE50901, GSE53072, GSE53157, GSE58689 and GSE65144). Except for GSE53072, GSE53157 and GSE65144, the remaining chip arrays revealed significantly upregulated expression of CCND1 in the TC tissues compared with non-cancerous tissues (P\<0.05; [Fig. 6B-N](#f6-mmr-22-03-2199){ref-type="fig"}). The GSE53072, GSE53157 and GSE65144 chip arrays displayed non-significant trends towards upregulated expression of CCND1 in the TC tissues. AROC curve analysis of CCND1 was also performed and the results are shown in [Fig. 7B-N](#f7-mmr-22-03-2199){ref-type="fig"}. Then, CCND1 expression data from TCGA and GEO databases, which provided 897 TC and 193 non-cancerous tissues, were subjected to meta-analysis. The pooled SMD of CCND1 was 1.83 (P\<0.001; 95% CI, 1.41--2.26; [Fig. 8A](#f8-mmr-22-03-2199){ref-type="fig"}) by the random effects model, and the test for heterogeneity was P\<0.01 (I^2^=79.9%). The sROC curve of the TCGA and GEO expression data is shown in [Fig. 8B](#f8-mmr-22-03-2199){ref-type="fig"}. The publication bias was evaluated by a funnel chart: Begg\'s test and Egger\'s test were 0.44 and 0.75, respectively, which indicated that there was no conspicuous publication bias among the datasets ([Fig. 8C and D](#f8-mmr-22-03-2199){ref-type="fig"}). Furthermore, the AUC of the sROC was 0.91 (95% CI, 0.89--0.94) and the combined sensitivity and specificity were 0.85 (95% CI, 0.81--0.89) and 0.98 (95% CI, 0.90--1.00), respectively. The results revealed that CCND1 may be a good biomarker to discriminate TC tissues from non-cancerous tissues.

### Validation of the targeting regulatory relation between miR-193a-3p and CCND1

The putative miR-193a-3p binding site in CCND1 3′ UTR was identified ([Fig. 9A](#f9-mmr-22-03-2199){ref-type="fig"}). The targeting regulatory association between miR-193a-3p and CCND1 was investigated in 293 cells following transfection with miR-193a-3p or miR-146b-5p mimics. The findings indicated that miR-193a-3p reduced the luciferase activity of the Wt CCND1 3′ UTR, demonstrating a direct combination between CCND1 and miR-193a-3p (P\<0.05; [Fig. 9B-D](#f9-mmr-22-03-2199){ref-type="fig"}). Furthermore, the luciferase activity of CCND1 3′ UTR (Mut) was not reduced in the mimic-transfected cells. miR-146-5p reduced the luciferase activity of the Wt TRAF6-3′ UTR, indicating that the experiment and its results were reliable. Pearson correlation analysis was also conducted to evaluate the association between miR-193a-3p and CCND1; however, no linear correlation was observed between CCND1 and miR-193a-3p (r=−0.163; [Fig. 9E](#f9-mmr-22-03-2199){ref-type="fig"}). The Human Protein Atlas database was utilized to explore the protein levels of CCND1. Consistent with the gene expression data, CCND1 protein expression was higher in TC than in non-cancerous tissues, as shown in [Fig. 10](#f10-mmr-22-03-2199){ref-type="fig"}.

Discussion
==========

TC is a frequent endocrine malignancy of the endocrine system ([@b72-mmr-22-03-2199]). The occurrence rate of TC has been increasing worldwide ([@b73-mmr-22-03-2199]). The main therapy method of TC is thyroidectomy and radioiodine treatment ([@b74-mmr-22-03-2199]). To the best of the authors\' knowledge, there is currently no effective drug for the treatment for TC. There is increasing evidence that abnormal miRNA expression levels give rise to TC tumorigenesis and progression. Prior studies have demonstrated that various miRNAs may aid in the diagnosis of TC and help formulate more individualized therapeutic management strategies ([@b75-mmr-22-03-2199]--[@b78-mmr-22-03-2199]). miR-193a-3p is involved in certain biological processes, including apoptosis, proliferation, invasion, metastasis and migration ([@b79-mmr-22-03-2199]). A number of studies have demonstrated that miR-193a-3p is expressed at low levels in different human cancers, including colon cancer ([@b80-mmr-22-03-2199]), lung cancer ([@b81-mmr-22-03-2199],[@b82-mmr-22-03-2199]), breast cancer ([@b28-mmr-22-03-2199]) and malignant pleural mesothelioma ([@b83-mmr-22-03-2199]). Nevertheless, the expression levels, as well as its mechanisms, in TC remain to be elucidated. Hence, a comprehensive meta-analysis was conducted to evaluate clinical valuation of miR-193a-3p in TC. GO, KEGG pathway and PPI analyses were performed to search for the latent biological mechanisms of miR-193a-3p in TC. The results indicated that CCND1 served as the most important hub gene. Subsequently, the relationship between miR-193a-3p and CCND1 was validated through a dual luciferase assay.

To the best of the authors\' knowledge, the present study is the first to survey the expression levels and clinical value of miR-193a-3p in TC by extracting expression data from TCGA, GEO and ArrayExpress. The present study primarily scrutinized the miR-193a-3p expression between 510 TC and 59 non-cancerous thyroid samples using TCGA database. The outcomes revealed that miR-193a-3p had low expression in TC. Subsequently, the GEO database and ArrayExpress were used to validate miR-193a-3p expression in TC. A total of 2 of the 4 chip arrays also revealed that a low miR-193a-3p expression is significant in TC. Although the remaining 2 chip arrays did not display a significant downregulation in TC tissues, they indicated the downregulated expression tendency of miR-193a-3p in TC. According to the results of the present study, miR-193a-3p may provide a biomarker to test the occurrence and development of TC. However, in the study by Santarpia et al ([@b31-mmr-22-03-2199]), the result was the opposite: miR-193a-3p was overexpressed in TC compared with non-cancerous groups. The observation of overexpressed miR-193a-3p may be caused by the small sample size of the study. That significantly downregulated miR-193a-3p in TC was observed in the present study was credible due to the quantity of sample data that was obtained from several public databases. Analysis of the sROC in miR-193a-3p from TCGA, GEO and ArrayExpress databases demonstrated that the expression levels may have a moderate ability to differentiate between TC patients and non-cancerous controls with an AUC of 0.80. At the same time, its sensitivity and specificity were 0.69 and 0.82, respectively. Additionally, downregulated miR-193a-3p was association with age, metastasis and sex in TCGA. Although the present study identified that downregulated miR-193a-3p was associated with age, metastasis and sex; how these factors regulate TC cells requires further investigation by *in vivo* and/or *in vitro* analysis.

At present, several studies have noted that abnormal miR-193a-3p expression has a pivotal effect on cell biological processes and leads to numerous pathological conditions ([@b79-mmr-22-03-2199],[@b80-mmr-22-03-2199],[@b84-mmr-22-03-2199]). For example, Pekow *et al* revealed that miR-193a-3p is a crucial neoplasm inhibitor in colon carcinoma and facilitates the progression of cancer ([@b80-mmr-22-03-2199]). Lin *et al* ([@b84-mmr-22-03-2199]). demonstrated that low miR-193a-3p expression is related to a poor disease outcome in colorectal carcinoma. In addition, miR-193a-3p suppresses cell multiplication in prostatic carcinoma by targeting CCND1 ([@b85-mmr-22-03-2199]). However, little research has been performed into the molecular mechanisms of miR-193a-3p in TC. To further study the underlying mechanisms regarding the regulation of miR-193a-3p in TC, the present study conducted a bioinformatics analysis of the candidate target genes of miR-193a-3p. A total of 28 candidate target genes of miR-193a-3p were gathered and GO analysis was performed, which indicated that the candidate target genes markedly assembled in 'response to nutrient levels' for BP, 'lamellar body' for CC and 'sulfur compound binding' for MF. GO analysis revealed that miR-193a-3p target genes were mainly concentrated in 'cell adhesion', which exerts an oncogenic role in the progression of TC. In addition, PPI analysis was performed, and it was found that CCND1 was situated at the core of the PPI network. CCND1 had the most connections among proteins, which may manifest in the way the gene contributes to TC.

A previous study by Li *et al* ([@b35-mmr-22-03-2199]) reported that CCND1 plays a key role in facilitating migration and tumor metastasis. Liang and Sun ([@b86-mmr-22-03-2199]) reported that an upregulation of CCND1 in thyroid cancer tissues is markedly associated with the clinical stage of TC, indicating that it could be considered as a biomarker in clinical settings. A study by Jeon *et al* ([@b87-mmr-22-03-2199]) showed that CCND1 is clearly overexpressed in TC, and may be involved in the occurrence and development of the disease. Lamba Saini *et al* ([@b88-mmr-22-03-2199]) demonstrated that CCND1 and its variants are significantly overexpressed in TC, and that it should serve as a diagnostic marker for TC. Investigating the mechanism of CCND1 expression levels is crucial due to the broader roles of CCND1 in TC tissues. From the present study, the results calculated from the TCGA database demonstrated that CCND1 exhibited a notably low expression in TC compared with non-cancerous tissues. However, differential expression of CCND1 was not obtained for the clinical parameters analyzed. The present study also included 13 microarrays from the GEO database. In addition to GSE53072, GSE53157, GSE6339 and GSE65144, other chip arrays all displayed a significant upregulation of CCND1 expression in TC compared to non-cancerous tissues. Although the remaining 4 chip arrays did not show statistical significance, they all showed an increasing trend in CCND1 expression levels in TC. From the sROC analysis of miR-193a-3p, the AUC was 0.91. The results showed that CCND1 may have a high value for differentiating TC from non-cancerous tissue and may serve as a prognostic biomarker in TC.

The study by Liu *et al* ([@b85-mmr-22-03-2199]) identified that miR-193a-3p acts as a key component inhibiting prostate cancer, which could induce G1-phase arrest by targeting CCND1. Chou *et al* ([@b25-mmr-22-03-2199]) demonstrated that miR-193a-3p suppresses the aggression and progression of gastric cancer by targeting CCND1 expression. Tsai *et al* ([@b89-mmr-22-03-2199]) also demonstrated that miR-193a-3p may serve as an underlying neoplasm inhibitor in breast carcinoma, which could inhibit cell growth by suppressing CCND1. To this end, the present study performed a dual luciferase assay, and a regulatory association between miR-193a-3p and CCND1 was validated. In summary, the findings of the present study revealed that miR-193a-3p may regulate CCND1 expression to affect the tumor cell cycle, cell proliferation, differentiation and metabolism. Nevertheless, further research is required to test this hypothesis.

However, in the present study, some limitations should be acknowledged. First, it lacks further *in vitro* and *in vivo* testing, such as reverse transcription-quantitative PCR. These methods are pivotal to enhancing the understanding of how miR-193a-3p works in relation to CCND1 in TC. Second, the present study only focused on the analysis of differential miRNAs in tissues. Other samples, such as blood, should also be assessed.

In summary, the present study gathered a great amount of data from TCGA, GEO, and ArrayExpress databases, and validated the clinical value of miR-193a-3p and CCND1. The results showed that miR-193a-3p expression was evidently downregulated in TC, while CCND1 expression was markedly upregulated. These results may help to diagnose TC and predict the prognosis of TC when thyroid tissues are obtained from a fine needle biopsy. Bioinformatics analysis was next performed to clarify the molecular mechanisms of miR-193a-3p. In light of the bioinformatics analysis, CCND1 was regarded as the most important hub gene in TC. Subsequently, a dual luciferase assay was performed to corroborate the targeting regulatory association between miR-193a-3p and CCND1. The results demonstrated that miR-193a-3p markedly contributes to TC via particular pathways, and both miR-193a-3p and CCND1 may serve as potential biological markers of TC.

Not applicable.

Funding
=======

This study was supported by Fund of National Natural Science Foundation of China (grant nos. NSFC81060202 and NSFC81260222), the Fund of Guangxi Key R&D Project Plan (grant no. AB17195020) and the Future Academic Star of Guangxi Medical University (grant nos. WLXSZX19050 and WLXSZX19055).

Availability of data and materials
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

YYP, HY, XJL and RW contributed to the design of the study; XJL and RW wrote the manuscript; DYW, PL, DHP, LJZ and YH collected the data, performed the statistical analysis and interpreted the data; and LS, YYQ, YHL, JNL, JLY, QQL, JW and JM contributed to the data collection and statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Validation of miR-193a-3p expression in different databases. (A) TCGA, (B) GSE40807, (C) GSE73182, (D) GSE62054 and (E) E-MTAB-736. miR, microRNA; TC, thyroid cancer; TCGA, The Cancer Genome Atlas.](MMR-22-03-2199-g00){#f1-mmr-22-03-2199}

![Receiver operating characteristic curve analysis of miR-193a-3p from TCGA and GEO databases. (A) TCGA, (B) GSE40807, (C) GSE73182, (D) GSE62054 and (E) E-MTAB-736. miR, microRNA; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; AUC, area under curve.](MMR-22-03-2199-g01){#f2-mmr-22-03-2199}

###### 

Meta-analysis of miR-193a-3p in TC. (A) Forest plot curve for evaluating miR-193a-3p expression in TC compared with non-cancerous tissues, the pooled SMD was −1.00 \[P\<0.001; 95% CI, −1.21-(−0.79)\]. (B) AUC of sROC Curve was 0.80 (95% CI, 0.76--0.83), which indicated a moderate ability to differentiate TC from non-cancer samples. The pooled sensitivity and specificity were 0.69 (95% CI, 0.59--0.78) and 0.82 (95% CI, 0.67--0.91), respectively. (C) Begg\'s test. (D) Egger\'s test. miR, microRNA; TC, thyroid cancer; SMD, standard mean difference; CI, confidence interval; AUC, area under curve; sROC, summary receiver operating characteristic; TCGA, The Cancer Genome Atlas.
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![Identification of miR-193a-3p -related target genes. (A) Venn diagram for overlap among GEO, TCGA and miRWalk. (B) Protein-protein interaction network of the target genes. Each node represents a protein. The lines represent the interaction between the proteins. Different line colors correspond to different types of interaction (blue, from curated databases; pink, experimentally determined; yellow, textmining; black, co-expression). GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.](MMR-22-03-2199-g04){#f4-mmr-22-03-2199}

###### 

Gene Ontology and disease ontology analyses of microRNA-193a-3p target genes. (A) Biological processes. (B) Cellular components. (C) Molecular functions. (D) Disease Ontology terms.
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![Upregulation of CCND1 in TC compared to non-cancerous tissues based on different databases. (A) TCGA, (B) GSE3678, (C) GSE6004, (D) GSE9115, (E) GSE27115, (F) GSE29265, (G) GSE33630, (H) GSE35570, (I) GSE50901, (J) GSE53072, (K) GSE53157, (L) GSE58689, (M) GSE65144 and (N) GSE6339. TC, thyroid cancer. CCND1, cyclin D1; TCGA, The Cancer Genome Atlas.](MMR-22-03-2199-g09){#f6-mmr-22-03-2199}

![Receiver operating characteristic curves of CCND1 expression for differentiating thyroid cancer from non-cancerous thyroid tissues. (A) The Cancer Genome Atlas, (B) GSE3678, (C) GSE6004, (D) GSE9115, (E) GSE27115, (F) GSE29265, (G) GSE33630, (H) GSE35570, (I) GSE50901, (J) GSE53072, (K) GSE53157, (L) GSE58689, (M) GSE65144 and (N) GSE6339 datasets. CCND1, cyclin D1; AUC, area under curve.](MMR-22-03-2199-g10){#f7-mmr-22-03-2199}

###### 

Meta-analysis of CCND1 from public databases. (A) Forest plot curve of the meta-analysis for evaluating CCND1 expression between TC and non-cancerous tissues, the merged SMD was 1.83 (P\<0.001; 95% CI, 1.41--2.26). (B) sROC of CCND1 in TC from TCGA and GEO databases was 0.91 (95% CI, 0.89--0.94), which demonstrated that CCND1 probably plays crucial role in distinguishing TC from non-cancerous tissues. The pooled sensitivity and specificity at 0.85 (95% CI, 0.81--0.89) and 0.98 (95% CI, 0.90--1.00), respectively. (C) Begg\'s test. (D) Egger\'s test. CCND1, cyclin D1; TC, thyroid cancer; SMD, standard mean difference; sROC, summary receiver operating characteristic; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus.
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![Dual luciferase assay. (A) miR-193a-3p binding site in the 3′ UTR region of CCND1. (B) After co-transfection into 293 cells, miR-193a-3p reduced the luciferase activity of the CCND1 3′ UTR (P\<0.05). TRAF6 3′ UTR + mimic-NC and TRAF6 3′ UTR + miR-146 were used as positive control. The x-axis represented the relative fluorescence value. The y-axis represented different test groups. \*P\<0.05. Expression of (C) miR-193a-3p and (D) miR-146 in 293 cells following transfection with mimic. \*\*P\<0.01, \*\*\*P\<0.001 vs. mimic control. (E) Pearson\'s correlation analysis between miR-193a-3p expression levels and CCND1 levels from TCGA (r=−0.163). miR, microRNA. miR, microRNA; CCND1, cyclin D1; TNFR6, tumor necrosis factor receptor associated factor 6; UTR, untranslated region; Wt, wild-type; Mut, mutant; NC, negative control.](MMR-22-03-2199-g13){#f9-mmr-22-03-2199}

![Immunohistochemical staining for CCND1 in thyroid cancer tissues from The Human Protein Atlas. (A and B) CCND1 expression was clearly observed in follicular adenoma carcinoma tissues (version 19.3; <http://www.proteinatlas.org/ENSG00000110092-CCND1/pathology/thyroid+cancer#img>). (C and D) CCND1 expression was not detected in normal thyroid tissues. Magnification, ×200 (version 19.3; <http://www.proteinatlas.org/ENSG00000110092-CCND1/tissue/Thyroid+gland#img>). CCND1, cyclin D1.](MMR-22-03-2199-g14){#f10-mmr-22-03-2199}

###### 

Association between miR-193a-3p expression and clinicopathological variables in TC from The Cancer Genome Atlas.

                                  miR-193a-3p expression            
  ------------------------- ----- ------------------------ -------- ---------
  Tissue                                                            
    Non-cancerous tissues   59    3.88±0.73                8.468    \<0.001
    TC                      510   3.00±0.75                         
  Sex                                                               
    Male                    134   2.89±0.73                −2.022     0.044
    Female                  368   3.04±0.76                         
  Pathologic tumor grade                                            
    Stage I--II             334   2.99±0.78                −0.459     0.647
    Stage III--IV           166   3.02±0.72                         
  Age                                                               
    \<60                    383   3.04±0.75                2.336      0.020
    ≥60                     119   2.86±0.77                         
  TNM stage                                                         
    T1-T2                   310   3.01±0.77                0.433      0.665
    T3-T4                   190   2.98±0.74                         
  Pathological lymph node                                           
    No                      229   2.96±0.75                −1.074     0.283
    Yes                     223   3.04±0.73                         
  Metastasis                                                        
    No                      278   3.03±0.76                1.990      0.048
    Yes                     9     2.52±0.95                         
  Ethnicity                                                         
    Caucasian               330   3.00±0.77                2.236      0.108
    African-American        27    2.69±0.73                         
    Asian                   52    3.01±0.68                         

miR, microRNA; TC, thyroid cancer.

###### 

General characteristics of included microarray and RNA sequencing datasets.

  Authors, year            Country   Dataset      Cancer group   Non-cancer groups   Refs.
  ------------------------ --------- ------------ -------------- ------------------- -------------------------
  TCGA, 2018               USA       TCGA         510            59                  --
  Lassalle *et al*, 2016   France    GSE40807     40             40                  ([@b42-mmr-22-03-2199])
  Stokowy *et al*, 2014    Norway    GSE62054     17             5                   Unpublished data
  Minna *et al*, 2016      Italy     GSE73182     19             5                   ([@b43-mmr-22-03-2199])
  Rossing *et al*, 2012    Denmark   E-MTAB-736   12             22                  ([@b44-mmr-22-03-2199])

TCGA, The Cancer Genome Atlas.

###### 

Enrichment GO and disease ontology terms of the target genes of microRNA-193a-3p.

  A, Biological processes                                                                          
  --------------------------- -------------------------------------------------------- ----------- -------------
  GO:0031667                  Response to nutrient levels                                6         5.58×10^−5^
  GO:0071900                  Regulation of protein serine/threonine kinase activity     6         6.50×10^−5^
  GO:0009991                  Response to extracellular stimulus                         6         8.06×10^−5^
                                                                                                   
  **B, Cellular component**                                                                        
                                                                                                   
  **ID**                      **Term**                                                 **Count**   **P-value**
                                                                                                   
  GO:0042599                  Lamellar body                                              2         2.91×10^−4^
  GO:0005771                  Multivesicular body                                        2         1.71×10^−3^
  GO:0045178                  Basal part of cell                                         2         2.06×10^−3^
                                                                                                   
  **C, Molecular function**                                                                        
                                                                                                   
  **ID**                      **Term**                                                 **Count**   **P-value**
                                                                                                   
  GO:1901681                  Sulfur compound binding                                    4         3.34×10^−4^
  GO:0008201                  Heparin binding                                            3         1.46×10^−3^
  GO:0098631                  Cell adhesion mediator activity                            2         1.87×10^−3^
                                                                                                   
  **D, DO terms**                                                                                  
                                                                                                   
  **ID**                      **Term**                                                 **Count**   **P-value**
                                                                                                   
  DOID:0060084                Cell type benign neoplasm                                10          2.79×10^−7^
  DOID:1575                   Rheumatic disease                                          6         1.12×10^−5^
  DOID:418                    Systemic scleroderma                                       6         1.12×10^−5^

GO, Gene Ontology; DO, Disease Ontology.

###### 

General characteristics of included microarray and RNA sequencing datasets.

  Authors, year                     Country    Dataset    Cancer group   Non-cancer groups   Refs.
  --------------------------------- ---------- ---------- -------------- ------------------- -------------------------
  TCGA, 2018                        USA        TCGA       513            59                  --
  Reyes *et al*, 2005               USA        GSE3678    7              7                   Unpublished data
  Vasko *et al*, 2007               USA        GSE6004    14             4                   ([@b57-mmr-22-03-2199])
  Fontaine *et al*, 2008            France     GSE6339    20             122                 ([@b58-mmr-22-03-2199])
  Salvatore *et al*, 2007           USA        GSE9115    15             4                   ([@b59-mmr-22-03-2199])
  Giordano *et al*, 2006            USA        GSE27155   78             21                  ([@b60-mmr-22-03-2199])
  Tomas *et al*, 2011               Belgium    GSE29265   29             20                  Unpublished data
  Dom *et al*, 2012                 Belgium    GSE33630   60             45                  ([@b61-mmr-22-03-2199])
  Handkiewicz-Junak *et al*, 2016   Poland     GSE35570   32             51                  ([@b62-mmr-22-03-2199])
  Barros-Filho *et al*, 2015        Brazil     GSE50901   61             4                   ([@b63-mmr-22-03-2199])
  Pita *et al*, 2014                Portugal   GSE53072   5              4                   ([@b64-mmr-22-03-2199])
  Pita *et al*, 2009                Portugal   GSE53157   24             3                   ([@b65-mmr-22-03-2199])
  Rusinek *et al*, 2015             Poland     GSE58689   27             18                  ([@b66-mmr-22-03-2199])
  von Roemeling *et al*, 2015       USA        GSE65144   12             13                  ([@b67-mmr-22-03-2199])

TCGA, The Cancer Genome Atlas.

###### 

Clinical parameters and CCND1 expression in TC from The Cancer Genome Atlas.

                                  CCND1 expression              
  ------------------------- ----- ------------------ ---------- ---------
  Tissue                                                        
    Non-cancerous tissues   59    11.66±0.49         −23.800    \<0.001
    TC                      513   13.36±0.74                    
  Sex                                                           
    Male                    136   13.33±0.80           −0.574     0.566
    Female                  369   13.37±0.72                    
  Pathologic tumor grade                                        
    Stage I--II             336   13.33±0.77           −1.269     0.205
    Stage III--IV           167   13.42±0.68                    
  Age                                                           
    \<60                    385   13.38±0.73           1.114      0.266
    ≥60                     120   13.30±0.78                    
  TNM stage                                                     
    T1-T2                   309   13.33±0.74           −1.148     0.251
    T3-T4                   194   13.41±0.74                    
  Pathological lymph node                                       
    No                      230   13.32±0.84           −1.849     0.065
    Yes                     225   13.44±0.55                    
  Metastasis                                                    
    No                      282   13.40±0.63           −0.662     0.508
    Yes                     9     13.55±0.71                    
  Ethnicity                                                     
    Caucasian               334   13.38±0.69           1.278      0.280
    African-American        27    13.58±0.43                    
    Asian                   51    13.45±0.73                    

CCND1, cyclin D1; TC, thyroid cancer.
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